Co-development Services

Co-development Services

Matching patients to your targeted therapy

We specialize in helping companies develop, validate and commercialize companion diagnostics and other in vitro diagnostic (IVD) tests, to help more patients benefit from targeted therapies

As your diagnostic partner, we’re here to support your therapeutic launch every step of the way — from discovery to commercialization.

Co-development Pathway

IVD Development

How ArcherDX develops companion diagnostics

1. Biomarker discovery

Areas of discovery
  • Tumor Profiling
  • Tumor Monitoring
  • Liquid Biopsy
  • Gene expression signatures
  • CAR-T tracking
  • Viral Integration
  • Immune sequencing
Discovery products
  • Use our assays
  • > 20 products available
  • All include design software and team
  • Design your own assays
  • > 16,000 primers in a single tube
  • Powered by our flexible AMP technology
Feasibility
  • We offer best-in-class panels and ability to assess feasibility in-house or in coordination with certified partners

2. Verification and validation

ISO Certified

We are ISO 13485:2016 certified to help with quality assurance and submission planning.

The flexibility to offer decentralized testing

Decentralized tests can help expedite recruiting and patient enrollment, in addition to helping retain clinical study participants — helping address logistical challenges and cost for study sponsors.

Global reach

ArcherDX has globally distributed products and CRO relationships worldwide

3. Commercialization

Commercialization

Our extensive knowledge in CDx commercialization allows us to support multiple approaches to your launch strategy, helping ensure every biomarker-eligible patient can receive your targeted therapy.

Learn more about our partnerships:
Collaboration with AstraZeneca to develop Personalized Cancer Monitoring (PCM) assays for MRD
Collaboration with Bayer to develop companion diagnostic to detect NTRK gene fusions

Ready to Start? Request A Consultation